Search
Life Sciences
Tubulis announced today that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to its lead antibody-drug conjugate (ADC) TUB-040 for the...
Tubulis announced today that the first patient has been treated in its first Phase I/IIa trial. The study is evaluating Tubulis’ next-generation antibody-drug conjugate (ADC)...
Source : La Gazette du LABORATOIRE
©LaGazetteDuLABORATOIRE
Starfish Bioscience aims to provide microbiological solutions to restore the soil microbiome for...
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...
Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing.
The participation of the Blue Forward FundTM, managed by Seventure Partners, and the PSIM fund, managed by Bpifrance on behalf of the French government, confirms the strong...
The company, has announced the completion of a $12 million Series C financing round. The round, co-led by SymBiosis and Khosla Ventures, reflects enthusiasm for Siolta's...
Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Maarten...
Starfish Bioscience today announced that it has raised €900,000 from Seventure Partners, the world's leading investor in the microbiome field through its Health for Life...
